AIVITA Biomedical Announces 96% Immune Response Against SARS-CoV-2 in Phase 2 Clinical Trial of a Personalized Vaccine

0 comments

About the Author

user

Related Posts

AIVITA Biomedical Appoints Dr. H. Christian Fibiger to its Board of Directors

AIVITA Biomedical CEO Dr. Hans Keirstead to Deliver Keynote at Festival of Biologics

AIVITA Biomedical CEO Dr. Hans Keirstead to Deliver Keynote At Vaccine World Asia Congress

AIVITA Biomedical CEO Dr. Hans Keirstead to Chair Keynote Panel and Deliver Talk at World Immunotherapy Congress Europe

More From This Category

AIVITA Biomedical Appoints Dr. H. Christian Fibiger to its Board of Directors

AIVITA Biomedical CEO Dr. Hans Keirstead to Deliver Keynote at Festival of Biologics

AIVITA Biomedical CEO Dr. Hans Keirstead to Deliver Keynote At Vaccine World Asia Congress

AIVITA Biomedical CEO Dr. Hans Keirstead to Chair Keynote Panel and Deliver Talk at World Immunotherapy Congress Europe